Hemoglobinopathies: Clinical Trials

22 trials for Hemoglobinopathies, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

8 completed, 4 recruiting, 2 not yet recruiting, 2 terminated. 22 Early Phase 1.

By phase and status

PhaseTrialsStatus
Early Phase 122Completed 8, Recruiting 4, Not yet recruiting 2, Terminated 2, Unknown 2, Withdrawn 2, Active not recruiting 1, Enrolling by invitation 1

Follow Hemoglobinopathies: new trials by email Literature Review of Hemoglobinopathies trials Research Report on Hemoglobinopathies

Trials (filtered) newest first · largest first

All 22 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
CS-206 in Patients With Sickle Cell Disease
CS-206 - Sickle Cell Disease
Early Phase 1Not yet recruitingChildren's Hospital of Fudan University52026-09-302026-05-15
YOLT-204 in Patients With Hemoglobinopathies
YOLT-204 - Hemoglobinopathies (Transfusion-dependent β-thalassemia and Sickle Cell Disease)
Early Phase 1Not yet recruitingGuangzhou Women and Children's Medical Center182025-09-302025-09-24
CS-206 in Patients With Sickle Cell Disease
CS-206 - Sickle Cell Disease
Early Phase 1RecruitingCorrectSequence Therapeutics Co., Ltd52024-09-022026-02-10
Determination of Red Cell Survival in Sickle Cell Disease and Other Hemoglobinopathies Using Biotin Labeling
Biotin-labeled red blood cells - Sickle Cell Disease, Thalassemia
Early Phase 1RecruitingNational Heart, Lung, and Blood Institute (NHLBI)1002024-05-172026-09-28
CS-101 in Patients With β-thalassemia
CS-101 - Beta-Thalassemia
Early Phase 1Enrolling by invitationCorrectSequence Therapeutics Co., Ltd102024-03-192026-06-09
Base-edited Autologous Hematopoietic Stem Cell Transplantation in Treating Patients With β-thalassemia Major
CS-101 injection - Beta-Thalassemia
Early Phase 1CompletedChildren's Hospital of Fudan University22023-11-072026-05-15
Safety and Efficacy of RM-004 Cells for Hemoglobin H-Constant Spring Disease
RM-004 - Alpha Thalassemia Hemoglobin H Constant Spring, Hemoglobinopathies
Early Phase 1RecruitingThe 923rd Hospital of Joint Logistics Support Force of People's Liberation Army52023-10-082024-06-03
A Clinical Study Evaluating the Safety and Efficacy of CS-101 in Treating Subjects With β-thalassemia
CS-101 - Beta-Thalassemia
Early Phase 1CompletedCorrectSequence Therapeutics Co., Ltd52023-08-262026-02-12
A Study Evaluating the Safety and Efficacy of LentiRed Drug Product in Transfusion-dependent β-Thalassemia [TDT]
GMCN-508B (LentiRed) - Transfusion Dependent Beta-Thalassemia
Early Phase 1RecruitingFirst Affiliated Hospital of Guangxi Medical University52023-02-222023-05-09
Alternative Dosing And Prevention of Transfusions (ADAPT)
Hydroxyurea - Sickle Cell Disease
Early Phase 1Active not recruitingChildren's Hospital Medical Center, Cincinnati1002022-06-162026-04-09
Red Cell Half Life Determination in Patients With and Without Sickle Cell Disease
Biotin label - Sickle Cell Disease, Sickle Cell Anemia
Early Phase 1CompletedNational Heart, Lung, and Blood Institute (NHLBI)222021-04-192024-02-13
Pre-transplant Immunosuppression and Donor Stem Cell Transplant for the Treatment of Severe Hemoglobinopathies
Bortezomib, Busulfan, Cyclophosphamide - Beta Thalassemia Major, Sickle Beta 0 Thalassemia
Early Phase 1WithdrawnM.D. Anderson Cancer Center2020-12-292024-10-24
RHD Genotype Matched Red Cells for Anti-D
D+ RH genotype matched red cell units for transfusion - Sickle Cell Disease, Anti-D Antibodies
Early Phase 1CompletedChildren's Hospital of Philadelphia52020-07-082025-05-02
A Dose-Finding Study of AG-348 in Sickle Cell Disease
AG-348 - Sickle Cell Disease
Early Phase 1CompletedNational Institutes of Health Clinical Center (CC)172019-07-112022-07-12
iHSCs With the Gene Correction of HBB Intervent Subjests With β-thalassemia Mutations
iHSCs treatment group - Thalassemia
Early Phase 1UnknownAllife Medical Science and Technology Co., Ltd.122019-01-012018-11-05
Stem Cell Transplant in Patients With Severe Sickle Cell Disease
Alemtuzumab, Total Body Irradiation, Sirolimus - Sickle Cell Disease
Early Phase 1TerminatedKathleen Dorritie12018-03-292022-06-28
Fetal Hemoglobin Induction Treatment Metformin
Metformin, Questionnaires - Sickle Cell Anemia, Sickle Cell Disease
Early Phase 1CompletedBaylor College of Medicine372017-03-022023-10-12
Therapeutic Effect of Colla Corii Asini on Improving Anemia and Hemoglobin Composition in Pregnant Women With Thalassemia
Colla corii asini - Thalassemia
Early Phase 1UnknownYanfang Li902015-03-012016-05-13
Androgen Regulation of Priapism in Sickle Cell Disease
Transdermal Androgel - Priapism, Sickle Cell Disease
Early Phase 1WithdrawnJohns Hopkins University2014-03-012017-01-19
Novel Dose Escalation to Predict Treatment With Hydroxyurea
Hydroxyurea - Sickle Cell Disease
Early Phase 1CompletedBaylor College of Medicine702013-10-012020-11-18

Showing 20 of 22. Sign in to see all of them.

Narrower conditions

Anemia, Sickle Cell (15)  ·  beta-Thalassemia (5)  ·  Thalassemia (3)  ·  Hematologic Diseases (2)  ·  Genetic Diseases, Inborn (1)  ·  Hypogonadism (1)  ·  Kidney Diseases (1)  ·  Priapism (1)  ·  Sickle Cell Trait (1)  ·  alpha-Thalassemia (1)

Broader conditions

Anemia (22)  ·  Anemia, Hemolytic (22)  ·  Anemia, Hemolytic, Congenital (22)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (22)  ·  Hemic and Lymphatic Diseases (22)  ·  Genetic Diseases, Inborn (21)  ·  Hematologic Diseases (20)  ·  Thalassemia (6)  ·  Male Urogenital Diseases (2)  ·  Urogenital Diseases (2)  ·  Endocrine System Diseases (1)  ·  Female Urogenital Diseases (1)  ·  Female Urogenital Diseases and Pregnancy Complications (1)  ·  Genital Diseases (1)

Interventions

Hydroxyurea (2)  ·  Alemtuzumab (1)  ·  Antilymphocyte Serum (1)  ·  Blood Transfusion (1)  ·  Bortezomib (1)  ·  Busulfan (1)  ·  CT-P10 (1)  ·  Calcium Dobesilate (1)  ·  Cyclophosphamide (1)  ·  Dexamethasone (1)  ·  Hematopoietic Stem Cell Transplantation (1)  ·  Losartan (1)  ·  Metformin (1)  ·  Mycophenolic Acid (1)  ·  Plasma Exchange (1)

Sponsors

CorrectSequence Therapeutics Co., Ltd (3)  ·  Baylor College of Medicine (2)  ·  Children's Hospital of Fudan University (2)  ·  Emory University (2)  ·  National Heart, Lung, and Blood Institute (NHLBI) (2)  ·  Allife Medical Science and Technology Co., Ltd. (1)  ·  Children's Hospital Medical Center, Cincinnati (1)  ·  Children's Hospital of Philadelphia (1)  ·  First Affiliated Hospital of Guangxi Medical University (1)  ·  Guangzhou Women and Children's Medical Center (1)  ·  Johns Hopkins University (1)  ·  Kathleen Dorritie (1)  ·  M.D. Anderson Cancer Center (1)  ·  National Institutes of Health Clinical Center (CC) (1)  ·  The 923rd Hospital of Joint Logistics Support Force of People's Liberation Army (1)

Countries

United States (10)  ·  China (9)  ·  Uganda (1)

Top investigators

Yongrong Lai, M.D. (3)  ·  John F Tisdale, M.D. (2)  ·  Xiaowen Zhai, M.D. (2)  ·  Alex George, MD, PhD (1)  ·  Ann Haight, M.D. (1)  ·  Arthur L Burnett, MD, MBA (1)  ·  Kathleen Dorritie, MD (1)  ·  Kris M Mahadeo (1)  ·  Marianne Yee, MD (1)  ·  Russell Ware, MD, PhD (1)  ·  Stella Chou, MD (1)  ·  Swee Lay Thein, M.D. (1)  ·  Titilope Fasipe, MD (1)  ·  Xinhua Zhang, MD (1)

Results publications

PMID 42705233, PMID 35576529, PMID 38181784, PMID 39172743, PMID 39265169, PMID 40222814, PMID 40441700, PMID 41809202, PMID 41951736, PMID 42376265

NIH funding

R01HL147879 (1)